Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 7 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Amicus Therapeutics Inc. maintains a portfolio with 12 pending office actions. These actions are situated within the Biotechnology & Pharmaceuticals technology area. The workload is distributed across 12 distinct examiners, which suggests a range of individual reviews for the pending matters. The portfolio is also associated with 8 distinct art units, indicating that some examiners are working within the same art units at the patent office.
The busiest examiner identified in the data is LANKFORD JR, LEON B, who is currently handling 1 busiest examiner pending action. This indicates that while there are 12 pending office actions in total, the workload is spread such that the busiest individual manages 1 busiest examiner pending action. This distribution across 12 distinct examiners results in many individual points of contact for the applicant.
The 8 distinct art units involved in the 12 pending office actions reflect the technical scope of the filings. The ratio of 12 distinct examiners to 8 distinct art units shows that the 12 pending office actions are not confined to a single examination group. With 12 pending office actions active, the company's strategy involves 12 distinct examiners across 8 distinct art units, including the 1 action under LANKFORD JR, LEON B.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (27%) |
| §112 only | 2 (18%) |
| Double-patenting + other | 1 (9%) |
| Multi-statute (no §101) | 4 (36%) |
| No statute on record | 1 (9%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANKFORD JR, LEON B | 1 | 70.0% | +31.6% |
| BRAUN, MADELINE E | 1 | 68.0% | +25.7% |
| NOAKES, SUZANNE MARIE | 1 | 73.3% | +18.2% |
| MEAH, MOHAMMAD Y | 1 | 70.8% | +42.7% |
| LOUNTOS, GEORGE THEMISTOCLIS | 1 | 57.1% | +60.0% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
| STEADMAN, DAVID J | 1 | 57.7% | +29.6% |
| NGUYEN, QUANG | 1 | 38.0% | +52.6% |
| LEE, CHIHYI NMN | 1 | 33.7% | +60.8% |
| TSAY, MARSHA M | 1 | 45.7% | +52.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17773416 | Recombinant CDKL5 Proteins, Gene Therapy and Production Methods | NGUYEN, QUANG | 27d |
| 18863111 | Methods for Treating Pompe Disease | LANKFORD JR, LEON B | — |
| 18040866 | Vesicle Targeting Proteins And Uses Of Same | LOUNTOS, GEORGE THEMISTOCLIS | — |
| 17909450 | Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene | INAM, SAHAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18111321 | Highly Potent Acid Alpha-Glucosidase With Enhanced Carbohydrates | MEAH, MOHAMMAD Y | 9d overdue |
| 17838741 | Recombinant Alpha-Galactosidase A For Treatment Of Fabry Disease | STEADMAN, DAVID J | 19d |
| 17773416 | Recombinant CDKL5 Proteins, Gene Therapy and Production Methods | NGUYEN, QUANG | 27d |
| 18863111 | Methods for Treating Pompe Disease | LANKFORD JR, LEON B | — |
| 18479396 | METHODS OF TREATING FABRY DISEASE IN PATIENTS HAVING A MUTATION IN THE GLA GENE | BRAUN, MADELINE E | — |
| 18473622 | Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene | NOAKES, SUZANNE MARIE | — |
| 18040866 | Vesicle Targeting Proteins And Uses Of Same | LOUNTOS, GEORGE THEMISTOCLIS | — |
| 17424979 | USE OF MIGALOSTAT IN REDUCING THE RISK OF CEREBROVASCULAR EVENT IN PATIENTS WITH FABRY DISEASE | LEE, CHIHYI NMN | — |
| Art Unit | Apps |
|---|---|
| 1656 | 3 |
| 1652 | 2 |
| 1624 | 1 |
| 1622 | 1 |
| 1631 | 1 |
| 1628 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18863111 | Methods for Treating Pompe Disease | LANKFORD JR, LEON B | — | §102§103 | Non-Final OA | — | Pending | Nov 05, 2024 |
| 18479396 | METHODS OF TREATING FABRY DISEASE IN PATIENTS HAVING A MUTATION IN THE GLA GENE | BRAUN, MADELINE E | 1624 | §102DPOther | Non-Final OA | — | Pending | Oct 02, 2023 |
| 18473622 | Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene | NOAKES, SUZANNE MARIE | 1656 | §112Other | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18111321 | Highly Potent Acid Alpha-Glucosidase With Enhanced Carbohydrates | MEAH, MOHAMMAD Y | 1652 | §112 | Non-Final OA | 9d overdue | Pending | Feb 17, 2023 |
| 18040866 | Vesicle Targeting Proteins And Uses Of Same | LOUNTOS, GEORGE THEMISTOCLIS | 1652 | §102§112 | Non-Final OA | — | Pending | Feb 07, 2023 |
| 17909450 | Methods Of Treating Fabry Disease In Patients Having A Mutation In The GLA Gene | INAM, SAHAR | 1622 | §103§112 | Non-Final OA | — | Pending | Sep 06, 2022 |
| 17838741 | Recombinant Alpha-Galactosidase A For Treatment Of Fabry Disease | STEADMAN, DAVID J | 1656 | §103 | Final Rejection | 19d | Pending | Jun 13, 2022 |
| 17773416 | Recombinant CDKL5 Proteins, Gene Therapy and Production Methods | NGUYEN, QUANG | 1631 | §102§103 | Non-Final OA | 27d | Pending | Apr 29, 2022 |
| 17424979 | USE OF MIGALOSTAT IN REDUCING THE RISK OF CEREBROVASCULAR EVENT IN PATIENTS WITH FABRY DISEASE | LEE, CHIHYI NMN | 1628 | §103Other | Final Rejection | — | Pending | Jul 22, 2021 |
| 17079859 | Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases | TSAY, MARSHA M | 1656 | Other | Non-Final OA | — | Pending | Oct 26, 2020 |
| 14398210 | DOSING REGIMENS FOR THE TREATMENT OF POMPE DISEASE | MOSS, NATALIE M | 1653 | §103 | Non-Final OA | — | Pending | Oct 31, 2014 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial